沙利度胺治疗原发性干燥综合征合并轻中度非特异性间质性肺炎疗效观察

doi:10.19723/j.issn.1671-167X.2021.02.030

Abstract

CLC Number:

R593.2

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 21

[1]	董笑影, 魏蔚. 沙利度胺治疗肺纤维化新进展[J]. 天津医科大学学报, 2015(3):272-274.
[2]	李丹, 刘学军, 杜毓峰. 沙利度胺治疗肺间质纤维化疗效的系统评价[J]. 国际呼吸杂志, 2014,34(14):1069-1074.
[3]	Warrick J, Bhalla M, Schabel S, et al. High resolution computed tomography in early scleroderma lung disease[J]. J Rheumatol, 1991,18(10):1520-1528. pmid: 1765976
[4]	Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2002,19(1):10-17. pmid: 12002379
[5]	郭强, 鲍春德. 结缔组织病与肺间质病变进展[J]. 上海医学, 2009,32(10):918-923.
[6]	Povysil C. Histopathological classification of idiopathic interstitial pneumonias[J]. Cesk Patol, 2010,46(1):3-7. pmid: 21280274
[7]	Kim DI, Lim YJ, Oh YH, et al. A case of Sjögren’s syndrome with multiple bullae secondary to pulmonary amyloidosis and lymphocytic infiltration of interstitium and bronchioles[J]. Tuberculosis & Respiratory Diseases, 1997,44(6):1426-1432.
[8]	Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren’s syndrome: A clinical, radiologic, and pathologic study[J]. Am J Respir Crit Care Med, 2005,171(6):632-638. pmid: 15579729
[9]	徐慧蓉, 马小兵, 王献华, 等. 肺纤维化相关因子研究进展[J]. 现代预防医学, 2011,38(10):1953-1955.
[10]	Zielonka TM. Angiogenesis in interstitial lung diseases[J]. Pneumonol Alergol Pol, 2009,77(1):52-60. pmid: 19308910
[11]	Okuma T, Terasaki Y, Kaikita K, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases[J]. J Pathol, 2004,204(5):594-604. pmid: 15538737
[12]	Tabata C, Tabata R, Takahashi Y, et al. Thalidomide prevents cigarette smoke extract-induced lung damage in mice[J]. Int Immunopharmacol, 2015,25(2):511-517. pmid: 25749497
[13]	Arai H, Furusu A, Nishino T, et al. Thalidomide prevents the progression of peritoneal fibrosis in mice[J]. Acta Histochem Cytochem, 2011,44(2):51-60. doi: 10.1267/ahc.10030 pmid: 21614166
[14]	Leiba M, Avigdor A. Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma: Response to Moreau[J]. Br J Haematol, 2015,168(4):604-605. doi: 10.1111/bjh.13125 pmid: 25252030
[15]	李冬, 徐丽艳, 常子娟, 等. 沙利度胺对百草枯诱导小鼠急性肺损伤的干预[J]. 中华劳动卫生职业病杂志, 2013,31(3):178-183.
[16]	Buckstein R, Kerbel R, Cheung M, et al. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis[J]. Leuk Res, 2014,38(7):756-763. pmid: 24819395
[17]	Tan H, Chen H, Xu C, et al. Role of vascular endothelial growth factor in angiodysplasia: An interventional study with thalidomide[J]. J Gastroenterol Hepatol, 2012,27(6):1094-1101. pmid: 22098296
[18]	Lechtzin N, Hilliard ME, Horton MR. Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis[J]. Chest, 2013,143(6):1745-1749. pmid: 23519393
[19]	Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic, pulmonary fibrosis: A randomized trial[J]. Ann Intern Med, 2012,157(6):398-406. pmid: 22986377
[20]	Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: Predicting response to therapy and survival[J]. Am J Respir Crit Care Med, 1998,157(4 Pt 1):1063-1072. pmid: 9563720
[21]	Dixon S, Benamore R. The idiopathic interstitial pneumonias: Understanding key radiological features[J]. Clin Radiol, 2010,65(10):823-831. pmid: 20797469

Related Articles 15

[1]	Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2]	Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183.
[3]	Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017.
[4]	Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023.
[5]	Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[6]	Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041.
[7]	Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8]	Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060.
[9]	Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066.
[10]	Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073.
[11]	Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[12]	Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095.
[13]	Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[14]	Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112.
[15]	Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Group	FVC%		FEV1%		DLco%
Group	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control (n=23)	74.99±2.13	75.99±1.95^*	72.82±1.91	74.17±2.12^*	62.75±1.89	67.43±2.75^*
Observation (n=26)	73.37±2.39	77.55±2.43^*#	72.65±1.48	75.91±1.49^*#	62.64±2.24	69.34±1.96^*#

Group	Before treatment	After treatment
Control (n=23)	9.18±2.75	7.91±2.52^*
Observation (n=26)	8.88±2.89	6.33±2.46^*#

Group	Physiology		Psychology
Group	Before treatment	After treatment	Before treatment	After treatment
Control (n=23)	5.37±0.46	5.66±0.45^*	5.29±0.52	5.53±0.51^*
Observation (n=26)	5.33±0.45	5.94±0.40^*#	5.18±0.41	5.85±0.36^*#
Group	Sociology		Total score
Group	Before treatment	After treatment	Before treatment	After treatment
Control (n=23)	5.33±0.46	5.54±0.50^*	15.99±1.15	16.74±1.17^*
Observation (n=26)	5.19±0.39	5.85±0.34^*#	15.71±1.13	17.63±0.93^*#

Group^a	Leukopenia	Stomach upset	Neurosensory abnormality	Constipation	Drowsiness
Control (n=22)	0	2 (9.1)	0	1 (4.5)	0
Observation (n=25)	1 (4.0)	2 (8.0)	1 (4.0)	3 (1.2)	6 (2.4)^*

RICH HTML

PDF (PC)

Abstract

Cite this article

share this article

Figures/Tables 4

References 21

Related Articles 15

Metrics

Comments

Recommended 0